title: Complement, cold agglutinins, and therapy.
abstract: In this issue of Blood, Shi and coworkers show that TNT003, a mouse monoclonal antibody targeting complement protein C1s, prevents induction of in vitro hemolysis by cold agglutinins (CA). If successfully transferred into the clinical setting by further studies, these findings may result in a novel therapeutic principle for a frequently difficult problem.
authors: HAUGESUND HOSPITAL.
authors: Sigbjørn
authors: S
authors: Berentsen
mesh_terms: D000744:Anemia, Hemolytic, Autoimmune / Q000188:drug therapy*; D000818:Animals; D058846:Antibodies, Monoclonal, Murine-Derived / Q000494:pharmacology*; D003167:Complement Activation / Q000187:drug effects*; D003173:Complement C1s / Q000037:antagonists & inhibitors*; D005260:Female; D006801:Humans; D008297:Male; D057057:Serine Proteases / Q000097:blood*; D015842:Serine Proteinase Inhibitors / Q000494:pharmacology*
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D015842:Serine Proteinase Inhibitors; D057057:Serine Proteases; D003173:Complement C1s